Table 9 γδ T cell-based cancer immunotherapies
Classification | Targets/Cells | Agents | Preclinical models or clinical trials |
|---|---|---|---|
γδ T cell engagers | TRGV9/HER2 | (Her2)2xVγ9 | Preclinical pancreatic cancer model |
TRGV9/EGFR | LAVA-1223 | Preclinical colon cancer model | |
TRGV9/CD1d | LAVA-051 | Leukemia and MM (NCT04887259) | |
TRGV9/CD40 | LAVA-1278 | Preclinical MM model | |
TRGV9/CD123 | LAVA-1266 | Preclinical AML model | |
BTN3A | ICT01 | Solid and hematological malignancies (NCT04243499 and NCT05307874) | |
Expanded γδ T cell transfer | Allogeneic Vγ9Vδ2 T cells | Unnamed product | Lung and liver cancers (NCT03183232 and NCT03183219) |
Allogeneic Vδ1 T (DOT) cells | GDX012 | AML (NCT05001451) | |
MGMT-modified γδ T cells | INB200 | Glioblastoma (NCT04165941) | |
γδTCR-engineered T cell transfer | Vγ9Vδ2 TCR-engineered αβ T cells | TEG002 | MM (NCT04688853) |
αβ T cells with anti-CD19 AbTCR | ET190L1 | Lymphoma (NCT03415399) | |
αβ T cells with anti-α-fetoprotein AbTCR and glypican-3-targeted co-stimulatory molecule | ET140203 | HCC (NCT04502082 and NCT04634357) | |
CAR-γδ T cells | NKG2DL-targeting CAR-γδ T cells | CTM-N2D | Solid tumors (NCT04107142) |
CD20-targeting CAR-γδ T cells | ADI-001 | B Cell Malignancies (NCT04735471 and NCT04911478) | |
Glypican-3-targeting CAR-γδ T cells expressing soluble IL-15 | ADI-002 | Preclinical HCC model | |
CD19-targeting CAR-γδ T cells | Unnamed product | Preclinical CD19+ leukemia model | |
MUC1-Tn-targeting CAR-γδ T cells | Unnamed product | Preclinical gastric cancer model | |
CD123-targeting CAR-DOT cells | Unnamed product | Preclinical AML model |